Galapagos NV (GLPG) Stock Price

GLPGStock

$30.19−20.78%52W

Market Cap—

P/E5.52x

PEG Ratio—

Div yield—

Beta0.18

GLPG Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-33.35%

Price vs S&P 500 (4W)3.98%

VGM Score71.89

P/E Ratio (Annual)5.52x

Book Value / Share (Quarterly)$55.80

P/TBV (Annual)0.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)26.30%

Cash Flow / Share (Quarterly)$-2.54

Price vs S&P 500 (YTD)3.27%

Gross Margin (TTM)98.43%

Net Profit Margin (TTM)86.88%

EPS (TTM)$10.16

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$10.16

Revenue Growth (5Y)15.97%

EPS (Annual)$5.47

ROI (Annual)9.90%

Gross Margin (Annual)97.33%

Net Profit Margin (5Y Avg)13.47%

Cash / Share (Quarterly)$38.29

P/E Basic Excl Extra (TTM)2.97x

Revenue Growth QoQ (YoY)-81.45%

P/E Normalized (Annual)5.52x

ROA (Last FY)9.42%

Revenue Growth TTM (YoY)78.00%

EBITD / Share (TTM)$7.88

ROE (5Y Avg)1.50%

Operating Margin (TTM)70.70%

Cash Flow / Share (Annual)$-4.62

P/B Ratio0.54x

P/B Ratio (Quarterly)0.53x

Net Income / Employee (Annual)$796,870

EV / Revenue (TTM)1.48x

Net Interest Coverage (TTM)-1.68x

ROA (TTM)17.01%

EPS Growth QoQ (YoY)3033.03%

EV / EBITDA (TTM)3.98x

EPS Incl Extra (Annual)$5.47

Current Ratio (Annual)20.15x

Quick Ratio (Quarterly)32.72x

3-Month Avg Trading Volume0.09M

52-Week Price Return-20.78%

P/E Incl Extra (TTM)2.97x

Revenue / Employee (TTM)$2,283,297

Tangible BV / Share (Quarterly)$42.96

P/S Ratio (Annual)1.59x

Asset Turnover (Annual)0.33x

52-Week High$31.90

Operating Margin (5Y Avg)-23.65%

EPS Excl Extra (Annual)$5.47

CapEx CAGR (5Y)-31.41%

Tangible BV CAGR (5Y)4.44%

26-Week Price Return-22.43%

Quick Ratio (Annual)20.00x

13-Week Price Return2.41%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)32.84x

Enterprise Value$1.84B

Revenue / Share Growth (5Y)15.68%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)3.76%

Revenue / Employee (Annual)$2,762,159

Inventory Turnover (Annual)0.81x

Pretax Margin (Annual)27.05%

Cash / Share (Annual)$51.07

3-Month Return Std Dev33.63%

Gross Margin (5Y Avg)89.02%

Net Income / Employee (TTM)$1,481,713

ROE (Last FY)9.92%

Net Interest Coverage (Annual)-1.20x

EPS Basic Excl Extra (Annual)$5.47

Receivables Turnover (TTM)23.22x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$10.16

Receivables Turnover (Annual)50.25x

ROI (TTM)19.48%

P/S Ratio (TTM)1.93x

Pretax Margin (5Y Avg)-1.53%

Revenue / Share (Annual)$18.95

Tangible BV / Share (Annual)$55.11

Price vs S&P 500 (52W)-42.99%

P/E Ratio (TTM)2.97x

EPS Growth TTM (YoY)331.50%

Year-to-Date Return9.58%

5-Day Price Return-0.45%

EPS Normalized (Annual)$5.47

ROA (5Y Avg)1.90%

Net Profit Margin (Annual)28.85%

Month-to-Date Return-0.38%

Cash Flow / Share (TTM)$-3.22

EBITD / Share (Annual)$5.97

Operating Margin (Annual)26.53%

LT Debt / Equity (Annual)0.58x

ROI (5Y Avg)1.51%

P/E Excl Extra (TTM)2.97x

LT Debt / Equity (Quarterly)0.32x

EPS Basic Excl Extra (TTM)$10.16

P/TBV (Quarterly)0.69x

P/B Ratio (Annual)0.57x

Inventory Turnover (TTM)1.19x

Pretax Margin (TTM)86.92%

Book Value / Share (Annual)$55.12

Price vs S&P 500 (13W)-0.27%

Beta0.18x

P/FCF (Annual)0.60x

Revenue / Share (TTM)$15.63

ROE (TTM)19.52%

52-Week Low$25.05

vGradeA

gGradeB

mGradeB

vgmGradeB

GLPG Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.61

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GLPGGalapagos NV	A	B	B	1.9x	78.0%	98.4%	—	$30.19
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Galapagos NV

Galapagos NV is a fully integrated biotechnology company developing medicines for oncology and immunology, with operations in Europe and the United States. Its pipeline includes CAR-T cell therapies for blood cancers and a TYK2 inhibitor for autoimmune diseases currently in Phase 2 development. The company generates the majority of its revenue from the United States market.